The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 03, 2022

Filed:

Oct. 27, 2016
Applicant:

Janssen Vaccines & Prevention B.v., Leiden, NL;

Inventors:

Jaroslaw Juraszek, Amsterdam, NL;

Davide Branduardi, London, GB;

Ronald Vogels, Linschoten, NL;

Robert Heinz Edward Friesen, Wassenaar, NL;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16C 20/50 (2019.01); G16C 20/20 (2019.01); G16C 20/30 (2019.01); G16B 20/50 (2019.01); G16C 20/62 (2019.01); G16C 20/70 (2019.01); G16B 15/30 (2019.01); C40B 30/04 (2006.01); G16B 20/30 (2019.01); C07K 1/107 (2006.01);
U.S. Cl.
CPC ...
G16C 20/50 (2019.02); C40B 30/04 (2013.01); G16B 15/30 (2019.02); G16B 20/30 (2019.02); G16B 20/50 (2019.02); G16C 20/20 (2019.02); G16C 20/30 (2019.02); G16C 20/62 (2019.02); G16C 20/70 (2019.02); C07K 1/107 (2013.01);
Abstract

A method of designing a D-polypeptide that binds with an L-target protein can include: identifying a polypeptide target having L-chirality; determining hotspot amino acids of a polypeptide ligand having L-chirality that have binding interactions with the L-target protein; determining transformations of side chains of the hotspot amino acids that retain the binding interactions with the target; generating inversed hotspot amino acids with chirality opposite to the one of the target; identifying a polypeptide having inverse chirality from the target protein, on which a combination of inversed hotspot amino-acid can be grafted without significantly changing their interactions with the target. The designed ligands can be processed and converted to D-ligands that bind with the L-target protein.


Find Patent Forward Citations

Loading…